{"id":37460,"date":"2023-04-03T11:53:30","date_gmt":"2023-04-03T09:53:30","guid":{"rendered":"https:\/\/kapitalpartner.dk\/?p=37460"},"modified":"2023-04-18T09:42:14","modified_gmt":"2023-04-18T07:42:14","slug":"danish-biotech-weekly","status":"publish","type":"post","link":"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly\/","title":{"rendered":"Danish Biotech Weekly"},"content":{"rendered":"\n

The past week<\/strong> Gubra A\/S went public on the main stock exchange in Copenhagen, raising 500 MDKK. The share price for Gubra is currently trading around the offer price of 110 DKK.<\/strong> <\/p>\n\n\n\n

11 of the 19 listed, Danish biotech companies have published news the past week. 11 of the companies had a positive development in their share price for the week and 7 companies have had a positive share price performance year to date.<\/strong><\/p>\n\n\n\n

\n
Registration for the Danish Biotech Weekly newsletter<\/strong><\/a><\/div>\n<\/div>\n\n\n\n

<\/p>\n\n\n\n

Company news the past week<\/strong><\/p>\n\n\n\n

Ascendis Pharma<\/strong><\/p>\n\n\n\n

No news past week<\/em><\/p>\n\n\n\n

Biosergen<\/strong><\/a><\/p>\n\n\n\n

Biosergen provides Phase 2 clinical development strategy update (LINK)<\/a><\/p>\n\n\n\n

Biosergen Q4 EBITDA Loss Widens To SEK 12.5 Mln – Significant Developments (LINK)<\/a><\/p>\n\n\n\n

Cessatech<\/strong><\/p>\n\n\n\n

No news past week<\/em><\/p>\n\n\n\n

CS Medica<\/strong><\/a><\/strong><\/p>\n\n\n\n

CS MEDICA A\/S: Notice of Extraordinary General Meeting (LINK)<\/a><\/p>\n\n\n\n

CS MEDICA has entered into agreement with investor regarding directed share issue of DKK 60M at DKK 28.13 per share (LINK)<\/a><\/p>\n\n\n\n

CS MEDICA has entered a joint venture regarding production of CS-MEDICA’s CANNASEN\u00ae CBD medical products in China and distribution of CANNASEN\u00ae CBD products to the Asian market (LINK) <\/a><\/p>\n\n\n\n

Medical Device Company Approved to Prolong MDR Transition Until 31. December 2028 (LINK)<\/a><\/p>\n\n\n\n

Curasight<\/strong><\/a><\/strong><\/p>\n\n\n\n

No news past week<\/em><\/p>\n\n\n\n

Evaxion Biotech<\/strong><\/p>\n\n\n\n

Evaxion Announces Increased Focus and Fast-Tracking of its New AI Discovery to Patients. (LINK) <\/a><\/p>\n\n\n\n

Expres2ion<\/strong><\/p>\n\n\n\n

ExpreS2ion to participate in upcoming events. (LINK)<\/a><\/p>\n\n\n\n

ExpreS2ion publishes prospectus in connection with its rights issue of units (LINK)<\/a><\/p>\n\n\n\n

Fluoguide<\/strong><\/p>\n\n\n\n

No news past week<\/em><\/p>\n\n\n\n

Genmab<\/strong><\/p>\n\n\n\n

Genmab Announces Appointment of Martine van Vugt to Chief Strategy Officer (LINK)<\/a><\/p>\n\n\n\n

Gubra<\/strong><\/p>\n\n\n\n

Gubra announces the result of its initial public offering (LINK) <\/a><\/p>\n\n\n\n

Initiator Pharma<\/strong><\/p>\n\n\n\n

No news past week<\/em><\/p>\n\n\n\n

IO Biotech<\/strong><\/p>\n\n\n\n

No news past week<\/em><\/p>\n\n\n\n

Pila Pharma<\/strong><\/p>\n\n\n\n

XEN-D0501 can progress to clinical trials up to 3-month duration after being found safe in 13-week preclinical oral safety studies. (LINK)<\/a><\/p>\n\n\n\n

Saniona<\/strong><\/p>\n\n\n\n

No news past week<\/em><\/p>\n\n\n\n

Scandion Oncology<\/strong><\/p>\n\n\n\n

Scandion Oncology – Annual Report 2022 (LINK)<\/a><\/p>\n\n\n\n

Scandion Oncology successfully completes the dose finding with lead compound SCO-101 in advanced pancreatic cancer patients (PANTAX phase Ib trial) (LINK)<\/a><\/p>\n\n\n\n

SynAct Pharma<\/strong><\/p>\n\n\n\n

SynAct Pharma introduces resomelagon as generic name for AP1189 (LINK)<\/a><\/p>\n\n\n\n

SynAct Pharma to host a Capital Markets Day in Stockholm on May 5, 2023 (LINK)<\/a><\/p>\n\n\n\n

ViroGates<\/strong><\/p>\n\n\n\n

ViroGates A\/S – ViroGates announces the publication of a new study that shows suPAR causes cardiovascular disease (LINK)<\/a><\/p>\n\n\n\n

Zealand Pharma<\/strong><\/p>\n\n\n\n

Increases its Share Capital as a Consequence of Exercise of Employee Warrants (LINK)<\/a> <\/p>\n\n\n\n

Zealand Pharma Announces Positive Phase 1 Clinical Results with Amylin Analogue ZP8396 (LINK)<\/a><\/p>\n\n\n\n

Zealand Pharma announces completion of a directed issue and private placement of 6,578,948 million new ordinary shares raising gross proceeds of DKK 1.5 billion (LINK)<\/a><\/p>\n\n\n\n

Y-mAbs Therapeutics<\/strong><\/p>\n\n\n\n

No news past week<\/em><\/p>\n\n\n\n

2cureX<\/strong><\/p>\n\n\n\n

No news past week<\/em><\/p>\n\n\n\n

<\/p>\n\n\n\n

Share price development<\/strong><\/p>\n\n\n\n

Y-mAbs Therapeutics Inc.<\/strong> became the best performing Danish biotech company last week with a 65% increase, even though they didn’t publish any news. At the opposite end of the spectrum was Expres2Ion Biotech Holding AB<\/strong>, which fell 10% after publishing the prospectus in connection with its rights issue of units. Since the start of the year, most of the companies have been under pressure, while especially Saniona AB, Curasight A\/S <\/strong>and Fluoguide AB<\/strong> has performed very well. Saniona has made a strong comeback after several years of downturns. This follows after a possible approval for the company’s lead-candidate in Mexcio, which could generate royalties for Saniona.<\/p>\n\n\n\n

Read more about Curasight and Fluoguide:<\/strong><\/mark> The unique cancer treatment of the future – Today’s investment<\/a><\/p>\n\n\n\n

\"\"<\/figure>\n","protected":false},"excerpt":{"rendered":"

The past week Gubra A\/S went public on the main stock exchange in Copenhagen, raising 500 MDKK. The share price for Gubra is currently trading around the offer price of 110 DKK. 11 of the 19 listed, Danish biotech companies have published news the past week. 11 of the companies had a positive development in […]<\/p>\n","protected":false},"author":11,"featured_media":37397,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[221],"tags":[],"class_list":["post-37460","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cs-medica-en"],"acf":[],"yoast_head":"\nDanish Biotech Weekly | Kapital Partner A\/S<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Danish Biotech Weekly | Kapital Partner A\/S\" \/>\n<meta property=\"og:description\" content=\"The past week Gubra A\/S went public on the main stock exchange in Copenhagen, raising 500 MDKK. The share price for Gubra is currently trading around the offer price of 110 DKK. 11 of the 19 listed, Danish biotech companies have published news the past week. 11 of the companies had a positive development in […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly\/\" \/>\n<meta property=\"og:site_name\" content=\"Kapital Partner A\/S\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/kapitalpartner\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-03T09:53:30+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-04-18T07:42:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/03\/Danish-Biotech-Weekly.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1015\" \/>\n\t<meta property=\"og:image:height\" content=\"533\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Anders S\u00f8ndergaard\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@KapitalPartner\" \/>\n<meta name=\"twitter:site\" content=\"@KapitalPartner\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Anders S\u00f8ndergaard\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly\/\"},\"author\":{\"name\":\"Anders S\u00f8ndergaard\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/person\/3225264862e39be271a9aff1c94009ed\"},\"headline\":\"Danish Biotech Weekly\",\"datePublished\":\"2023-04-03T09:53:30+00:00\",\"dateModified\":\"2023-04-18T07:42:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly\/\"},\"wordCount\":564,\"publisher\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#organization\"},\"image\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/03\/Danish-Biotech-Weekly.png\",\"articleSection\":[\"CS Medica\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly\/\",\"url\":\"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly\/\",\"name\":\"Danish Biotech Weekly | Kapital Partner A\/S\",\"isPartOf\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/03\/Danish-Biotech-Weekly.png\",\"datePublished\":\"2023-04-03T09:53:30+00:00\",\"dateModified\":\"2023-04-18T07:42:14+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly\/#primaryimage\",\"url\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/03\/Danish-Biotech-Weekly.png\",\"contentUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/03\/Danish-Biotech-Weekly.png\",\"width\":1015,\"height\":533},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/kapitalpartner.dk\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Investment cases\",\"item\":\"https:\/\/kapitalpartner.dk\/en\/category\/investment-cases\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Sector cases\",\"item\":\"https:\/\/kapitalpartner.dk\/en\/category\/investment-cases\/sector-cases\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Danish Biotech Weekly\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/kapitalpartner.dk\/#website\",\"url\":\"https:\/\/kapitalpartner.dk\/\",\"name\":\"Kapital Partner A\/S\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/kapitalpartner.dk\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/kapitalpartner.dk\/#organization\",\"name\":\"Kapital Partner A\/S\",\"url\":\"https:\/\/kapitalpartner.dk\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png\",\"contentUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png\",\"width\":496,\"height\":432,\"caption\":\"Kapital Partner A\/S\"},\"image\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/kapitalpartner\",\"https:\/\/x.com\/KapitalPartner\",\"https:\/\/www.linkedin.com\/company\/10438322\",\"https:\/\/www.youtube.com\/channel\/UCODuY5PE_fxmp2nSSsq3l3w\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/person\/3225264862e39be271a9aff1c94009ed\",\"name\":\"Anders S\u00f8ndergaard\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/27b1d0514d528cdb7505c72f554afadc?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/27b1d0514d528cdb7505c72f554afadc?s=96&d=mm&r=g\",\"caption\":\"Anders S\u00f8ndergaard\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Danish Biotech Weekly | Kapital Partner A\/S","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly\/","og_locale":"en_US","og_type":"article","og_title":"Danish Biotech Weekly | Kapital Partner A\/S","og_description":"The past week Gubra A\/S went public on the main stock exchange in Copenhagen, raising 500 MDKK. The share price for Gubra is currently trading around the offer price of 110 DKK. 11 of the 19 listed, Danish biotech companies have published news the past week. 11 of the companies had a positive development in […]","og_url":"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly\/","og_site_name":"Kapital Partner A\/S","article_publisher":"https:\/\/www.facebook.com\/kapitalpartner","article_published_time":"2023-04-03T09:53:30+00:00","article_modified_time":"2023-04-18T07:42:14+00:00","og_image":[{"width":1015,"height":533,"url":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/03\/Danish-Biotech-Weekly.png","type":"image\/png"}],"author":"Anders S\u00f8ndergaard","twitter_card":"summary_large_image","twitter_creator":"@KapitalPartner","twitter_site":"@KapitalPartner","twitter_misc":{"Written by":"Anders S\u00f8ndergaard","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly\/#article","isPartOf":{"@id":"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly\/"},"author":{"name":"Anders S\u00f8ndergaard","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/person\/3225264862e39be271a9aff1c94009ed"},"headline":"Danish Biotech Weekly","datePublished":"2023-04-03T09:53:30+00:00","dateModified":"2023-04-18T07:42:14+00:00","mainEntityOfPage":{"@id":"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly\/"},"wordCount":564,"publisher":{"@id":"https:\/\/kapitalpartner.dk\/#organization"},"image":{"@id":"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly\/#primaryimage"},"thumbnailUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/03\/Danish-Biotech-Weekly.png","articleSection":["CS Medica"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly\/","url":"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly\/","name":"Danish Biotech Weekly | Kapital Partner A\/S","isPartOf":{"@id":"https:\/\/kapitalpartner.dk\/#website"},"primaryImageOfPage":{"@id":"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly\/#primaryimage"},"image":{"@id":"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly\/#primaryimage"},"thumbnailUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/03\/Danish-Biotech-Weekly.png","datePublished":"2023-04-03T09:53:30+00:00","dateModified":"2023-04-18T07:42:14+00:00","breadcrumb":{"@id":"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly\/#primaryimage","url":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/03\/Danish-Biotech-Weekly.png","contentUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/03\/Danish-Biotech-Weekly.png","width":1015,"height":533},{"@type":"BreadcrumbList","@id":"https:\/\/kapitalpartner.dk\/en\/danish-biotech-weekly\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/kapitalpartner.dk\/en\/"},{"@type":"ListItem","position":2,"name":"Investment cases","item":"https:\/\/kapitalpartner.dk\/en\/category\/investment-cases\/"},{"@type":"ListItem","position":3,"name":"Sector cases","item":"https:\/\/kapitalpartner.dk\/en\/category\/investment-cases\/sector-cases\/"},{"@type":"ListItem","position":4,"name":"Danish Biotech Weekly"}]},{"@type":"WebSite","@id":"https:\/\/kapitalpartner.dk\/#website","url":"https:\/\/kapitalpartner.dk\/","name":"Kapital Partner A\/S","description":"","publisher":{"@id":"https:\/\/kapitalpartner.dk\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/kapitalpartner.dk\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/kapitalpartner.dk\/#organization","name":"Kapital Partner A\/S","url":"https:\/\/kapitalpartner.dk\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/","url":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png","contentUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png","width":496,"height":432,"caption":"Kapital Partner A\/S"},"image":{"@id":"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/kapitalpartner","https:\/\/x.com\/KapitalPartner","https:\/\/www.linkedin.com\/company\/10438322","https:\/\/www.youtube.com\/channel\/UCODuY5PE_fxmp2nSSsq3l3w"]},{"@type":"Person","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/person\/3225264862e39be271a9aff1c94009ed","name":"Anders S\u00f8ndergaard","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/27b1d0514d528cdb7505c72f554afadc?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/27b1d0514d528cdb7505c72f554afadc?s=96&d=mm&r=g","caption":"Anders S\u00f8ndergaard"}}]}},"_links":{"self":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts\/37460"}],"collection":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/comments?post=37460"}],"version-history":[{"count":1,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts\/37460\/revisions"}],"predecessor-version":[{"id":37461,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts\/37460\/revisions\/37461"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/media\/37397"}],"wp:attachment":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/media?parent=37460"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/categories?post=37460"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/tags?post=37460"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}